Oricell Therapeutics
PrivateLast Round
Growth Equity
Apr 9, 2026
Total Funding Raised
$305.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Oricell Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Growth Equity round in April 2026.
Oricell Therapeutics is a biotechnology company that develops innovative and affordable immunotherapies for unmet medical needs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oricell Therapeutics Comparables
Compare Oricell Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbelZeta Pharma | 87% | |
| Beijing Yimiao Shenzhou Pharmaceutical Technology | 87% | |
| TCRCure Biopharma | 86% |
For institutional investors. Book with your work email.
Oricell Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Apr 9, 2026 | ||||
| Series C | Jan 12, 2026 | ||||
| Series B Extension | Feb 28, 2023 | ||||
| Series B | Aug 1, 2022 | ||||
| Early Funding | Dec 1, 2019 | ||||
Angel | Feb 1, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Oricell Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Beijing E-Town International Investment & Development Co., Ltd. | Series C, Growth Equity |
| 健壹资本 | Series B |
| Boquan Equity Investment Management | Series B |
| Xiamen C&D Emerging Industry Equity Investment | Series B Extension |
| Talon Capital | Series C |
| Elēkrŏn Ventures | Series C, Growth Equity |
| NGS Super | Series C, Growth Equity |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2026
Open roles increased to 19, representing 79% of headcount.
- Aug 21, 2026
Monthly visitors grew 774% MoM, from 200 to 1.7K.
For institutional investors. Book with your work email.
Oricell Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oricell Therapeutics's valuation, stock price, and market status.
Is Oricell Therapeutics a public or private company?
Oricell Therapeutics is a private company.
What is the current stock price of Oricell Therapeutics?
Oricell Therapeutics is a private company, so its shares have no public market price. Caplight tracks Oricell Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oricell Therapeutics worth (valuation)?
Valuation information for Oricell Therapeutics is not publicly available.
Can I buy Oricell Therapeutics stock?
Oricell Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oricell Therapeutics's last funding round?
Oricell Therapeutics's most recent funding round was Growth Equity on April 9, 2026.
Who are the main investors in Oricell Therapeutics?
Key investors in Oricell Therapeutics include RTW Investments, Qiming Venture Partners, Vivo Capital, Qatar Investment Authority, Quan Capital.
Will Oricell Therapeutics IPO soon?
No public IPO plans have been announced for Oricell Therapeutics.
How can I track Oricell Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Oricell Therapeutics's shares on secondary markets.